Bangshun Pharmaceutical files for second Hong Kong IPO attempt
AI摘要- Bangshun Pharmaceutical filed a second listing application with the Hong Kong Stock Exchange.
- Revenue totaled 943,000 yuan in 2024, 509,000 yuan in 2025 and zero in early 2026.
- Bezegratinib received Chinese approval in April 2026 for treating myelofibrosis.